TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Uterine Cancer Market

3.3       Key Market Trends

3.3.1    Drivers

3.3.2    Restraints

3.3.3    Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1    Bargaining Power of Suppliers

3.4.2    Bargaining Power of Buyers

3.4.3    Threat of Substitution

3.4.4    Threat of New Entrants

3.4.5    Competitive Rivalry

3.5       Market Share Analysis

4          By Type Overview

4.1       Introduction

4.1.1    Market Size & Forecast (Value)

4.2       Endometrial Adenocarcinoma

4.2.1    Market Size & Forecast (Value)

4.3       Adenosquamous Carcinoma

4.3.1    Market Size & Forecast (Value)

5          By Treatment Overview

5.1       Introduction

5.1.1    Market Size & Forecast (Value)

5.2       Diagnosis

5.2.1    Market Size & Forecast (Value)

5.3       Therapeutic Treatment

5.3.1    Market Size & Forecast (Value)

6          Regional Overview

6.1       Introduction

6.1.1    Market Size & Forecast (Value)

6.2       America

6.2.1    North America

6.2.1.1 U.S.

6.2.1.1.1          By Type

6.2.1.1.2          By Treatment

6.2.1.2 Canada

6.2.1.2.1          By Type

6.2.1.2.2          By Treatment

6.2.1.3 Mexico

6.2.1.3.1          By Type

6.2.1.3.2          By Treatment

6.2.4    Latin America

6.2.1.4.1          By Type

6.2.1.4.2          By Treatment

6.3       Europe

6.3.1    Market Size & Forecast (Value)

6.3.2    Germany

6.3.2.1          By Type

6.3.2.2          By Treatment

6.3.3    France

6.3.3.1          By Type

6.3.3.2          By Treatment

6.3. 4   U.K

6.3.4.1          By Type

6.3.4.2          By Treatment

6.3.5    Italy

6.3.5.1          By Type

6.3.5.2          By Treatment

6.3.6    Spain

6.3.6.1          By Type

6.3.6.2          By Treatment

6.3.7    Rest of Europe

6.3.7.1          By Type

6.3.7.2          By Treatment

6.4       Asia Pacific

6.4.1    Market Size & Forecast (Value)

6.4.2    Japan

6.4.2.1          By Type

6.4.2.2          By Treatment

6.4.3    China

6.4.3.1          By Type

6.4.3.2          By Treatment

6.4.4    Australia

6.4.4.1          By Type

6.4.4.2          By Treatment

6.4.5    India

6.4.5.1          By Type

6.4.5.2          By Treatment

6.4.6    South Korea

6.4.6.1          By Type

6.4.6.2          By Treatment

6.4.7    Rest of Asia-Pacific

6.4.7.1          By Type

6.4.7.2          By Treatment

6.5       Middle East & Africa

6.5.1    Market Size & Forecast (Value)

6.5.2    Saudi Arabia

6.5.2.1          By Type

6.5.2.2          By Treatment

6.5.3    South Africa

6.5.3.1          By Type

6.5.3.2          By Treatment

6.5.4    Kuwait

6.5.4.1          By Type

6.5.4.2          By Treatment

6.5.5    Rest of Middle East & Africa

6.5.5.1          By Type

6.5.5.2          By Treatment

7          Company Profile

7.1       Novartis AG

7.1.1    Company Overview

7.1.2    Financial Performance

7.1.3    Recent Developments

7.1.4    Product Portfolio

7.2       Merck & Company, Inc.

7.2.1    Company Overview

7.2.2    Financial Performance

7.2.3    Recent Developments

7.2.4    Product Portfolio

7.3       R-Pharm-US LLC.

7.3.1    Company Overview

7.3.2    Financial Performance

7.3.3    Recent Developments

7.3.4    Product Portfolio

7.4       Actiza Pharmaceutical Private Limited

7.4.1    Company Overview

7.4.2    Financial Performance

7.4.3    Recent Developments

7.4.4    Product Portfolio

7.5       Pfizer Inc.

7.5.1    Company Overview

7.5.2    Financial Performance

7.5.3    Recent Developments

7.5.4    Product Portfolio

7.6       United Biotech Pvt Ltd

7.6.1    Company Overview

7.6.2    Financial Performance

7.6.3    Recent Developments

7.6.4    Product Portfolio

7.7       Bristol-Myers Squibb Company

7.7.1    Company Overview

7.7.2    Financial Performance

7.7.3    Recent Developments

7.7.4    Product Portfolio

7.8       Elder Pharmaceuticals Ltd

7.8.1    Company Overview

7.8.2    Financial Performance

7.8.3    Recent Developments

7.8.4    Product Portfolio

            7.9       Par Pharmaceutical Companies, Inc.

7.8.1    Company Overview

7.8.2    Financial Performance

7.8.3    Recent Developments

7.8.4    Product Portfolio